Table 2 The adjusted relative risks and 95% confidence intervals of all-cause cancer incidence according to quartiles of each lipid component

 Range, mg/dL

82–158

207–660

 Cases

46

71

 Incidence rate

3.7

 Model 1

1

1.01 (0.65–1.57)

0.97

1.25 (0.82–1.90)

0.30

1.07 (0.70–1.63)

 Model 2

1

0.95 (0.61–1.47)

0.81

1.09 (0.72–1.66)

0.69

0.91 (0.59–1.39)

 Model 3

1

1.00 (0.63–1.58)

0.99

1.07 (0.69–1.67)

0.77

0.92 (0.58–1.46)

 Range, mg/dL

38–96

97–113

114–132

133–252

 Cases

43

61

71

65

 Incidence rate

3.5

4.3

4.9

4.6

 Model 1

1

1.12 (0.73–1.73)

0.61

1.18 (0.77–1.80)

0.45

1.01 (0.66–1.56)

 Model 2

1

1.04 (0.67–1.61)

0.85

1.02 (0.66–1.56)

0.94

0.86 (0.55–1.33)

 Model 3

1

1.07 (0.68–1.69)

0.76

0.93 (0.59–1.48)

0.77

0.89 (0.56–1.42)

 Range, mg/dL

28–74

75–102

103–152

153–774

 Cases

46

55

62

76

 Incidence rate

3.6

4.2

4.4

5.4

 Model 1

1

1.01 (0.66–1.56)

0.95

1.00 (0.66–1.53)

0.98

1.06 (0.70–1.61)

 Model 2

1

0.89 (0.57–1.38)

0.60

0.83 (0.54–1.27)

0.38

0.82 (0.53–1.28)

 Model 3

1

0.80 (0.50–1.27)

0.34

0.80 (0.51–1.25)

0.33

0.82 (0.52–1.31)

 Range, mg/dL

55–104

105–124

125–148

149–631

 Cases

43

60

66

71

 Incidence rate

3.5

4.4

4.5

5.0

 Model 1

1

1.03 (0.66–1.59)

0.90

1.06 (0.69–1.61)

0.80

0.99 (0.65–1.52)

 Model 2

1

0.92 (0.59–1.43)

0.71

0.87 (0.56–1.33)

0.52

0.80 (0.51–1.23)

 Model 3

1

0.92 (0.58–1.45)

0.70

0.79 (0.50–1.26)

0.32

0.82 (0.51–1.31)